LPL Financial
MGX icon

LPL Financial’s Metagenomi Therapeutics MGX Stock Holding History

LPL Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,834
Closed -$22.6K – 6374
2026
Q1 		$22.6K Buy
16,834
+5,537
+49% +$8.6K ﹤0.01% 5866
2025
Q4 		$18.3K Buy
+11,297
New +$24.5K ﹤0.01% 5814

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Catalio Capital Management
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
Peapod Lane Capital
Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pura Vida Investments
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LPL Financial's MGX Position: Q2 2026 in Review

LPL Financial sold out of Metagenomi Therapeutics (MGX) in Q2 2026, closing a stake of 16,834 shares — an estimated $22.6K sold.

LPL Financial first reported a position in MGX in Q4 2025 and held it in 2 quarters. The position peaked at $22.6K in Q1 2026. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • LPL Financial reported no remaining Metagenomi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • LPL Financial sold 16,834 Metagenomi Therapeutics shares in Q2 2026, an estimated $22.6K.
  • LPL Financial first reported a position in Metagenomi Therapeutics in Q4 2025 and held it in 2 quarters.
  • LPL Financial's Metagenomi Therapeutics position peaked at $22.6K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.